These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 33230660)

  • 1. New Drug and Biologics Approvals in 2019: A Systematic Analysis of Patient Experience Data in FDA Drug Approval Packages and Product Labels.
    Schultz-Knudsen K; Sabaliauskaite U; Hellsten J; Lassen AB; Morant AV
    Ther Innov Regul Sci; 2021 May; 55(3):503-513. PubMed ID: 33230660
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FDA Reported Use of Patient Experience Data in 2018 Drug Approvals.
    Kieffer CM; Miller AR; Chacko B; Robertson AS
    Ther Innov Regul Sci; 2020 May; 54(3):709-716. PubMed ID: 33301134
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FDA Reported Use of Patient Experience Data in 2018 Drug Approvals.
    Kieffer CM; Miller AR; Chacko B; Robertson AS
    Ther Innov Regul Sci; 2019 Oct; ():2168479019871519. PubMed ID: 31597462
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Role of Real-World Evidence in FDA-Approved New Drug and Biologics License Applications.
    Purpura CA; Garry EM; Honig N; Case A; Rassen JA
    Clin Pharmacol Ther; 2022 Jan; 111(1):135-144. PubMed ID: 34726771
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessment of PRO label claims granted by the FDA as compared to the EMA (2006-2010).
    DeMuro C; Clark M; Doward L; Evans E; Mordin M; Gnanasakthy A
    Value Health; 2013 Dec; 16(8):1150-5. PubMed ID: 24326168
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FDA's Benefit-Risk Framework for Human Drugs and Biologics: Role in Benefit-Risk Assessment and Analysis of Use for Drug Approvals.
    Lackey L; Thompson G; Eggers S
    Ther Innov Regul Sci; 2021 Jan; 55(1):170-179. PubMed ID: 32779045
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A review of patient-reported outcome labels in the United States: 2006 to 2010.
    Gnanasakthy A; Mordin M; Clark M; DeMuro C; Fehnel S; Copley-Merriman C
    Value Health; 2012 May; 15(3):437-42. PubMed ID: 22583453
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Review of Patient-Reported Outcomes Labeling for Oncology Drugs Approved by the FDA and the EMA (2012-2016).
    Gnanasakthy A; Barrett A; Evans E; D'Alessio D; Romano CD
    Value Health; 2019 Feb; 22(2):203-209. PubMed ID: 30711065
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potential of patient-reported outcomes as nonprimary endpoints in clinical trials.
    Gnanasakthy A; Lewis S; Clark M; Mordin M; DeMuro C
    Health Qual Life Outcomes; 2013 May; 11():83. PubMed ID: 23675876
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Innovating by developing new uses of already-approved drugs: trends in the marketing approval of supplemental indications.
    DiMasi JA
    Clin Ther; 2013 Jun; 35(6):808-18. PubMed ID: 23726388
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FDA Approval and Regulation of Pharmaceuticals, 1983-2018.
    Darrow JJ; Avorn J; Kesselheim AS
    JAMA; 2020 Jan; 323(2):164-176. PubMed ID: 31935033
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Accelerated approval drug labels often lack information for clinical decision-making.
    Ballreich J; Socal M; Bennett CL; Xuan A; Trujillo A; Anderson G
    Pharmacotherapy; 2023 Apr; 43(4):300-304. PubMed ID: 36872463
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reasons for rejection of patient-reported outcome label claims: a compilation based on a review of patient-reported outcome use among new molecular entities and biologic license applications, 2006-2010.
    DeMuro C; Clark M; Mordin M; Fehnel S; Copley-Merriman C; Gnanasakthy A
    Value Health; 2012 May; 15(3):443-8. PubMed ID: 22583454
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current Practices and Challenges When Submitting Patient Experience Data for Regulatory Decisions by the US Food and Drug Administration: An Industry Survey.
    Pinto CA; Tervonen T; Jimenez-Moreno C; Levitan B; Soriano Gabarró M; Girman C; Norquist JM; Hauber B
    Patient; 2024 Mar; 17(2):147-159. PubMed ID: 38085458
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patient-Reported Outcomes in Chronic Heart Failure: Applicability for Regulatory Approval.
    Psotka MA; von Maltzahn R; Anatchkova M; Agodoa I; Chau D; Malik FI; Patrick DL; Spertus JA; Wiklund I; Teerlink JR
    JACC Heart Fail; 2016 Oct; 4(10):791-804. PubMed ID: 27395351
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Proposed study designs for approval based on a surrogate endpoint and a post-marketing confirmatory study under FDA's accelerated approval regulations for disease modifying osteoarthritis drugs.
    Kraus VB; Simon LS; Katz JN; Neogi T; Hunter D; Guermazi A; Karsdal MA
    Osteoarthritis Cartilage; 2019 Apr; 27(4):571-579. PubMed ID: 30465809
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of Patient and Investigator Global Impression Scales: A Review of Food and Drug Administration-Approved Labeling, 2009 to 2019.
    Gnanasakthy A; Barrett A; Norcross L; D'Alessio D; Romano CD
    Value Health; 2021 Jul; 24(7):1016-1023. PubMed ID: 34243825
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patient-reported outcomes supporting anticancer product approvals.
    Rock EP; Kennedy DL; Furness MH; Pierce WF; Pazdur R; Burke LB
    J Clin Oncol; 2007 Nov; 25(32):5094-9. PubMed ID: 17991927
    [TBL] [Abstract][Full Text] [Related]  

  • 19. US FDA's Dose Optimization Postmarketing Requirements and Commitments of Oncology Approvals and the Impact on Product Labels from 2010 to 2022: An Emerging Landscape from Traditional to Novel Therapies.
    Gendy JM; Nomura N; Stuart JN; Blumenthal G
    Ther Innov Regul Sci; 2024 Mar; 58(2):380-386. PubMed ID: 38182940
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Examination of the relationship between oncology drug labeling revision frequency and FDA product categorization.
    Berlin RJ
    Am J Public Health; 2009 Sep; 99(9):1693-8. PubMed ID: 19372515
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.